Ad is loading...
MENU

BEAM Stock Beam Therapeutics (BEAM, $25.29) entered Uptrend as Momentum indicator ascends above 0 level on Nov 19, 2024

A.I.dvisor
at Tickeron.com
Loading...
BEAM - Beam Therapeutics
Momentum signal
Bullish Trend
Odds of UP Trend
Tickeron
Momentum signal
Price: $25.29
Daily change: +$1.17 (+4.85%)
Daily volume: 1.2M
Industry: Biotechnology
This indicator may be signaling that BEAM's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 94 similar cases where BEAM's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:

BEAM in upward trend: 10-day moving average broke above 50-day moving average on November 11, 2024

The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 11, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BEAM moved out of overbought territory on November 12, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 20, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BEAM as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BEAM turned negative on November 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

BEAM moved below its 50-day moving average on November 20, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BEAM broke above its upper Bollinger Band on November 11, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.467) is normal, around the industry mean (13.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.241). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.798). BEAM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (5.519) is also within normal values, averaging (221.024).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
238 Main Street
Phone
+1 857 327-8775
Employees
436
Web
https://www.beamtx.com